Medicare advisers give vote of confidence to $93,000 drug Provenge for prostate cancer WASHINGTON (AP) -- Medicare advisers on Wednesday supported the effectiveness of the prostate cancer drug Provenge, an innovative therapy that has prompted questions about the cost of medical care and the government's role in paying for it. The vote by a 14-member panel of outside experts amounts to a recommendation that Medicare pay for Provenge, which costs $93,000 per patient and extends life an average of four months. The Centers for Medicare and Medicaid Services will make a final decision on the drug in March, and a...